Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pyxis OncologyPYXS +1.26%27 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates PYXS with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Pyxis Oncology ranks worse than 73.12% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Pyxis Oncology's Net Income for the
three
months ended in Mar. 2026 was $-23.27 Mil. Pyxis Oncology's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Pyxis Oncology's net margin for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Pyxis Oncology's Net Margin % or its related term are showing as below:
PYXS'
s Net Margin % Range Over the Past 10 Years
Min: -589.8 Med: -526.75 Max: -478.95
Current: -589.8
PYXS's Net Margin % is ranked worse than 73.12% of 945
companies
in the Biotechnology industry
Industry Median: -83.18
vs PYXS: -589.80
Pyxis Oncology (NAS:PYXS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Pyxis Oncology Net Margin % Related Terms
Pyxis Oncology Net Margin % Historical Data
* Premium members only.
The historical data trend for Pyxis Oncology's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pyxis Oncology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pyxis Oncology Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pyxis Oncology's Net Margin % distribution charts can be found below:
* The bar in red indicates where Pyxis Oncology's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pyxis Oncology (PYXS) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Pyxis Oncology and its competitors. According to the industry distribution chart, Pyxis Oncology ranks #691 out of 945 companies in the Biotechnology industry, placing it in the top 73.1%.
Is Pyxis Oncology's Net Margin % too high?
Pyxis Oncology's current Net Margin % is 0.00%. Based on the distribution chart, Pyxis Oncology ranks #691 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pyxis Oncology has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Pyxis Oncology's Net Margin % compare to ORMP and CAMP?
According to the Biotechnology industry distribution chart, Pyxis Oncology ranks #691 out of 945 companies for Net Margin %. This places Pyxis Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Pyxis Oncology and its competitors. Pyxis Oncology's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pyxis Oncology stock overvalued right now?
Pyxis Oncology (PYXS) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Pyxis Oncology's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Pyxis Oncology (PYXS), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
27GF Score
Get the complete analysis for PYXS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PYXS has been successfully added to your 
